Elizabeth Park

Frazier Management invests in lower middle-market healthcare companies with $5-50 million in EBITDA and makes equity commitments ranging from $30-350 million. Investments take the form of buyouts, recapitalizations and corporate carveouts.

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

MacuSight, Inc. develops and manufactures pharmaceuticals products. The firm engages in developing therapeutics for the treatment of severe ocular diseases and conditions. It offers sirolimus, a therapeutic for the treatment and prevention of wet age-related macular degeneration, as well as for the treatment of diabetic macular edema; and related compounds and other select therapeutics in the eye, as well as minimally-invasive ocular formulations. The company was founded in 2003 and is headquartered in Union City, CA.